



Claims

1. A compound selected from: *N*-(2-[2-dimethylaminoethyl-methylamino]-5-[[4-(1*H*-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl)-prop-2-enamide:



and

N-(4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-[methyl-(2-methylaminoethyl)amino]phenyl)prop-2-enamide:



or a pharmaceutically acceptable salt thereof.

2. The compound as claimed in claim 1 which is: *N*-(2-[2-dimethylaminoethyl-methylamino]-5-[[4-(1*H*-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl)-prop-2-enamide.
3. The compound as claimed in claim 1 which is: *N*-(4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-[methyl-(2-methylaminoethyl)amino]phenyl)prop-2-enamide.
4. A pharmaceutical composition, which comprises a compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, in association with a pharmaceutically-acceptable diluent or carrier.
5. A compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, for use as a medicament.
6. A compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, for use in the treatment of cancer.
7. A compound or a pharmaceutically acceptable salt thereof, as claimed in claim 6, wherein the cancer is non-small cell lung cancer.

8. A compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, for use in the treatment of a disease mediated through L858R EGFR mutant and/or T790M EGFR mutant and/or the Exon19 deletion activating mutant.
9. A pharmaceutical product comprising the compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, and an additional anti-tumour substance for the conjoint treatment of cancer.
10. The pharmaceutical product as claimed in claim 9, wherein the cancer is non-small cell lung cancer.
11. The compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, and an additional anti-tumour substance for use in the conjoint treatment of cancer.
12. The compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, and an additional anti-tumour substance for use in the conjoint treatment of non-small cell lung cancer.